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Throughout the genetic and physiological evolution of microorganisms, the microbiological sciences have been
expanding the introduction of new therapeutic trials against microbial diseases. Special attention has been paid to
the bacterium Helicobacter pylori, which induces gastric infections capable of causing damage, ranging from acute
and chronic gastritis to the development of gastric cancer and death. The use of compounds with natural origins
has gained popularity in scientific research focused on drug innovation against H. pylori because of their broad
flexibility and low toxicity. The aim of this study was to describe the use of natural products against H. pylori in
order to clarify important parameters for related fields. The study demonstrated the vast therapeutic possibilities for
compounds originating from natural sources and revealed the need for innovations from future investigations to
expand the therapeutic arsenal in the fight against H. pylori infection.
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No decorrer da evolução genética e fisiológica dos micro-organismos, as ciências microbiológicas encontram-se em
expansão, preocupando-se em introduzir novas triagens terapêuticas frente às afecções microbianas, com especial
atenção àquelas adquiridas pela bactéria Helicobacter pylori, sendo esta frequentemente envolvida nas infecções
gástricas capazes de causar dano ao organismo humano que vão desde gastrites agudas e crônicas ao
desenvolvimento de neoplasias gástricas, levando o paciente ao óbito na maioria das vezes. Neste sentido, o uso
de compostos de procedência natural ganha destaque em pesquisas científicas voltadas a inovação medicamentosa
contra o H. pylori, visto a vasta flexibilidade de investigação terapêutica e a característica de baixa toxicidade. Este
trabalho teve como objetivo descrever sobre o uso de produtos naturais frente ao combate do H. pylori, a fim de
esclarecer parâmetros importantes para todas as áreas afins. O estudo demonstrou quão vasta são as possibilidades
terapêuticas exercidas por compostos oriundos de fontes da natureza e, verificou a necessidade de inovações
voltadas ao aprofundamento de investigações com o intuito de ampliação do arsenal terapêutico frente ao combate
do micro-organismo em questão.
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The relationship between Helicobacter pylori and acquired
resistance to various drugs from conventional therapy is
of worldwide concern. Several global consensus sessions
have been conducted to ensure that medical guidelines are
consistently updated on various issues involving the man-
agement of infection [1]. The first “Asian-Pacific H. pylori
Consensus Conference” took place in Singapore in August
1997, and since then, new scientific information concern-
ing the treatment of infection by this bacterium has been
published along with updates from conferences in North
America and Europe [2]. With antibiotic resistance reach-
ing a crisis point in countless medical and scientific
centers around the world and the growing resistance rate
affecting communities, there is an urgent need to restore
the arsenal of antimicrobial agents [3]. In addition to the
high rate of resistance observed in conventional therapy,
the chances of abandoning the treatment are large, mainly
due to side effects or recurrence of infection. Therefore,
it is extremely important to search for new therapeutic
sources with anti-Helicobacter pylori action. Currently,
plants are viewed as the main source for the discovery
of new compounds [4].
The use of natural products in the therapeutic manage-
ment against diseases caused by microorganisms such as
H. pylori presents advantages over drugs derived from
synthetic sources. This is due to the low side effects of
these drugs when their toxicological and pharmacological
activity is compared to those obtained from industrial
sources. In addition to the lower toxicity, areas such as
gastroenterology and bacteriology have shown remark-
able interest in the pharmacological activities that nat-
ural products have against infectious agents. The health
sciences have been increasingly concerned with the exac-
erbated growth in the number of H. pylori strains multi-
resistant to antibiotics currently used in clinical practice.
This may be explained by the indiscriminate use of drug
therapies leading to a higher incidence of failures in
treatment [5-7].
Given the numerous benefits provided by natural
products according to the literature, this paper presents
a bibliographical survey of reports of antimicrobial action
exerted by them against Helicobacter pylori published
between the years 1996 and 2013, with the purpose of




Identified in Australia (1982) by the researchers Barry
Marshall and J. Robin Warren, Helicobacter pylori was
isolated from gastric biopsy specimens from patients
with chronic gastritis and peptic ulcers [1,4,8]. It was dif-
ficult to demonstrate that this pathogen was really themajor cause of gastritis, peptic ulcer and gastric cancer;
therefore, to convince his teammates and the entire
audience, Barry Marshall took a suspension of the patho-
gen and confirmed by means of Koch’s postulates that H.
pylori was the major cause of gastric pathologies [9].
H. pylori is classified as a Gram-negative, spiral and
microaerophilic bacterium that specifically colonizes the
gastric mucosa and affects more than half of the world’s
population. In most cases, it is acquired in childhood
and, if left untreated, often persists into adulthood. Its
helical shape favors movement driven by flagella, causing
a disruption in the protective stomach lining. In associ-
ation with the release of cytokines and the chronic inflam-
matory process, this disruption can develop into more
serious and acute diseases, such as chronic gastritis, peptic
ulcer and gastric cancer [10-12].
H. pylori is considered one of the most common causes
of infection globally. The World Health Organization
(WHO) ranked the pathogen as a Class I carcinogen for
gastric cancer based on the results of epidemiological stu-
dies demonstrating its ability to induce carcinogenesis
without the administration of co-carcinogens [2,10,13].
Based on this, H. pylori quickly became the subject of sev-
eral studies in various health areas ranging from microbio-
logical to histological, epidemiological, immunological,
and ecological [1,8].
First-line treatment consists of triple and quadruple
therapies. Triple therapy includes a proton pump inhibi-
tor (PPI) such as omeprazole combined with two antibi-
otics, usually amoxicillin and clarithromycin. Quadruple
therapy contains one additional drug containing bismuth.
Sequential therapy is a simple dual therapy regimen in-
cluding a PPI plus amoxicillin given for the first 5 days,
followed by triple therapy including a PPI, clarithromycin
and tinidazole (all twice daily) for the remaining 5 days
[14]. Triple therapy has an efficacy of 75% but is expensive
and associated with drug resistance and numerous side
effects, such as observed with allergy and cardiovascu-
lar drugs, while sequential therapy has an efficacy of
90% or greater. However, this approach may fail be-
cause bacteria can oscillate between a replicative state
(microorganism remains susceptible to the antibiotic)
and a non-replicative state (microorganism becomes
resistant phenotype) according to the pH of its micro-
environment. The bacteria cannot enter the replicative
cycle when the pH is between 4.0 and 6.0, and the micro-
organisms are difficult to eradicate when they assume the
phenotypically resistant state (Figure 1) [15,16].
Virulence factors
Currently, urease, vacuolizing cytotoxin and pathogenicity
gene products (cagPAI - cag pathogenicity island) are con-
sidered to be the major virulence factors of the pathogen
[17]. Some strains of H. pylori have a pathogenicity island
Figure 1 United of replication of H. pylori (antibiotic sensitivity), and a non-replicative state (antibiotics insensitivity). Cycles occurring
according to the pH in the microenvironment. PPI: proton pump inhibitor, A: amoxicillin, C: clarithromycin [14].
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which in combination with the vacuolizing cytotoxin
(Vac A) results in a higher degree of virulence [12].
The pathogenicity of the bacteria is increased by the
presence of PAI; thus, H. pylori can be classified as cag +
or cag-. The proteins encoded by the cag PAI are res-
ponsible for inducing secretion of interleukin-8 (IL-8),
remodeling the surface of epithelial cells and forming the
pedestal. H. pylori can be divided into two types: type I
expresses cagA+ associated with cytotoxin VacA, whereas
type II does not express cagA associated with vacA. VacA
has the ability to induce large cytoplasmic vacuoles in
eukaryotic cells, which can lead to cell death [12].
H. pylori interacts closely with epithelial cells, causing
a variety of responses via diverse molecular interactions
such as the release of cytokines capable of activating
inflammatory cells. The type IV secretion system (T4SS)
transfers the CagA oncoprotein into the host cell
cytoplasm, where it becomes phosphorylated and affects
different cellular processes. This is considered the direct
contact of T4SS with the epithelial cell membrane; how-
ever, it is believed to be primarily responsible for the in-
duction of IL-8 and other host immune responses. The
α5β1 epithelial integrin has been implicated as one of
the host receptors involved in this activity. However, the
expression of these integrins is limited to the basolateral
membrane. A monolayer in vitro model of epithelial
cells with narrow junction integrity and measurable bar-
rier function would facilitate the study of H. pylori-hostcellular interactions and allow detailed examinations of
the molecular events that occur apical and basolaterally
during infection by the pathogen [10].
BabA is a protein present in the membrane of the bac-
teria that ensures adhesion to the epithelial cell. These
circular fibrillar structures cover the microorganism and
hamper its elimination by peristaltic movements, allow-
ing the secretion of factors that attract and stimulate
inflammatory cells [12].
It is believed that during the course of infection, there
is an increase in gastric acid and gastrin secretion. This
relationship has drawn the attention of many researchers
from different scientific fields seeking therapeutic alter-
natives that may behave favorably given all the factors
involved [18].
Because the gastric mucosa is considered to be the main
habitat of H. pylori, its survival in an acidic medium is
of the utmost importance. This survival is ensured by
the urease enzyme, which is capable of hydrolyzing the
urea present under physiological conditions in acidic
medium. The production of ammonia that occurs through
this hydrolysis acts as a receptor for H+ ions and con-
sequently generates a neutral pH in the intracellular
environment. Urease and ammonia promote destabili-
zation of the mucus layer, leading to formation of le-
sions on the lining cells. Furthermore, urease may also
be involved in the activation of neutrophils, monocytes
and the immune system, resulting in local inflamma-
tory lesions [12,19].
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colonization and H. pylori survival. The serine protease
HtrA has been found in most infected individuals and is
thus considered to be essential for the survival of the
bacteria. Lysosomal cathepsins and metalloproteases are
abundant proteases found during the early stages of H.
pylori-mediated pathogenesis. Therefore, this class of
protease enzymes may play a functional role in the
carcinogenesis of the stomach [20].
The occurrence of monochloramine is also related to
gastric injuries detected in the presence of H. pylori.
This derivative creates large amounts of ammonia [19]
and activates neutrophils that produce hypochlorous acid
to react with the amino acid taurine, forming taurine-
chloramine. Chloramines can be either short or long term
and have hydrophilic or lipophilic characters. The lipo-
philic character is long term and exhibits a better degree
of diffusion across the plasma membrane, causing oxida-
tive damage to various biomolecules [21,22].
Major pathologies associated with the presence of
Helicobacter pylori
The Helicobacter pylori bacterium is characterized as the
causative agent of various types of gastric pathologies. It
is often involved in cases of chronic gastritis, functional
dyspepsia, peptic or duodenal ulcers, and cancer or gas-
tric lymphomas. Because it can survive in acidic environ-
ments, it remains intact in the stomach and promotes
the destruction of the gastric mucosa. This makes the
organ sensitive and vulnerable to triggering of ulcerative
lesions and blocks the sterilization of food, producing
failures in the digestion process. Patients who have
chronic gastritis have a higher risk for the development
of peptic ulcers and carcinomas with increased severity.
This risk is especially problematic in individuals with chro-
nic multifocal atrophic gastritis, a type of autoimmune dis-
ease in which antibodies attack the mucosal lining of the
stomach, causing thinning and loss of many or all of the
cells that produce acid and enzymes. This disorder is most
commonly observed in the elderly, although there is also a
tendency for it to occur in people who have had part of
their stomach extirpated (a surgical procedure called par-
tial gastrectomy). Atrophic gastritis may cause pernicious
anemia because it interferes with the absorption of vitamin
B12 from food. The symptoms of gastritis in general are
burning, abdominal pain, loss of appetite, nausea, vomiting,
feeling of satiety and gastrointestinal bleeding. Deficiency
in absorption of elements and vitamins may also occur,
causing weakness and diarrhea [23-25].
Currently, dyspeptic syndrome or functional dyspepsia
is characterized as a common universal problem pre-
senting several disorders, especially peptic diseases de-
termined by chloridropeptic dysfunction; these include
gastroesophageal reflux disease and gastroduodenal pepticulcer. Although occurring with less intensity, infection
with H. pylori is directly linked to the development of this
pathology, with a significant reduction or complete elim-
ination observed when the patient is subjected to treat-
ment with drugs to combat the bacterium [26-28].
Among all the diseases caused by this pathogen, the
greatest focus is given to the development of stomach
cancer. This type of pathology is ranked fourth in the
world and is directly related to both the progress of
the malignant action of the microorganism and genetic
predispositions.
Estimates of incidence and mortality due to cancer
conducted by the National Cancer Institute (INCA)
show that 20,090 new cases of gastric cancer were fore-
cast for 2012 in Brazil, with 63% in men. Approximately
65% of patients diagnosed with gastric cancer are more
than 50 years old, with a peak incidence at approxi-
mately 70 years of age [28].
According to Antunes et al. [29], despite the efforts
made by various areas in health (such as gastroenterology
and microbiology) for the decline and prevention in pre-
valence of microorganisms in the host, infection with H.
pylori remains the greatest risk factor for the development
of gastric cancer, increasing the incidence risk for this
cancer approximately six-fold. With worldwide prevalence
estimated at between 50 and 90%, this type of cancer fre-
quently occurs in developing countries. In countries such
as China with high incidence rates of H. pylori, there is an
intense parallelism with gastric cancer. Most malignant
tumors occurring in the stomach environment are of ad-
enomatous origin, classified according to Lauren’s classifi-
cation into two main histological types: well-differentiated
or intestinal, and diffuse or poorly differentiated [30]. Ac-
cording to Argent et al. [31], incidences of gastric cancer
are associated with the presence of H. pylori with a posi-
tive profile for the CagA + gene, but factors such as diet
and genetic polymorphisms are directly related to the
onset of the pathology and degree of intensity. Moreover,
the combination of polymorphisms of proinflammatory
cytokines and infection arising from strains with high
virulence profiles influences the malignant carcinogenesis
process. Silva et al. [32] confirmed the association of hali-
tosis with the presence of Helicobacter pylori, especially
when an imbalance occurs in the oral ecosystem due to a
decrease in salivary flow or the presence of periodontal
disease. Although the stomach may be considered the
main reservoir of bacteria in men, oral cavities may be
considered as the second, thus allowing the isolation of
H. pylori in dental biofilms, saliva and gingival sulcus.
Natural extracts and essential oils used against
Helicobacter pylori
The various activities presented by natural products are
directly related to the presence of bioactive compounds.
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sponsible for many of them. Several studies have sought
the mechanism of action by which flavonoids contribute
to anti-H. pylori activity. Several studies have shown that
compounds from the flavonoid and chalcone classes in-
hibit the enzyme urease, which is secreted by the bacter-
ium during infection to ensure its survival in the acid
pH of the stomach. This may to some extent explain the
in vivo activity of the quercetin flavonoid against H.
pylori in Guinea pigs, as well as the efficacy of sofalcone
(a derivative of chalcone) in various drugs that comprise
the treatment of infection by this pathogen. Neverthe-
less, other mechanisms can also explain the activity of
flavonoids, such as VacA neutralization and interference
with toll-like receptor 4 signaling (TLR4). It is also
possible that certain flavonoids may exert direct activity
against H. pylori or act synergistically with antibiotics
used in conventional therapy [3].
Several natural products have demonstrated antimicro-
bial activity against H. pylori, and for centuries, a wide
variety of plants and substances derived from alternative
sources have been used in the treatment of gastrointes-
tinal disorders [4]. Data presented in world literature dem-
onstrates significant results obtained from plant extractsTable 1 Anti-Helicobacter pylori activity of plants
Scientific name Family Plant part use
Feijoa sellowiana (Berg.) Burret. Myrtaceae Fruit
Strychnos pseudoquina A. St. Hil. Loganiaceae Leaves
Bixa orellana L. Bixaceae Seed
Chamomilla recutita L. Asteraceae Inflorescence
Ilex paraguariensis A. St.-Hil. Aquifoliaceae Green leaves
Ilex paraguariensis A. St.-Hil. Aquifoliaceae Roasted Leaves
Malva sylvestris L. Malvaceae Inflorescence a
Plantago major L. Plantaginaceae Above-ground
Rheum rhaponticum L. Polygonaceae Root
Punica granatum L. Punicaceae Peel
Juglans regia L. Juglandaceae Fruit ridge
Davilla elliptica St. Hil. Dilleniaceae Leaves
Davilla nítida (Vahl.) Kubitzki. Dilleniaceae Leaves
Byrsonima fagifolia Niedenzu (IK.) Malpighiaceae Leaves
Qualea parviflora Mart. Vochysiaeceae Bark
Hancornia speciosa Gomez Apocynaceae Bark
Byrsonima intermedia A. Juss. Malpighiaceae Leaves
Larrea divaricata Cav. Zygophyllaceae Leaves and ten
Hericium erinaceus Hericiaceae Mushrooms
Allium sativum L. Liliaceae Bulb
Pistacia lentiscus (L.) var. chia (Duham) Anacardiaceae Mastic gum(Table 1) against H. pylori, generating significant contribu-
tions and increasing the therapeutic arsenal used in infec-
tious cases.
According to Brazilian Pharmacopoeia [33], an extract
can be defined as a preparation of liquid, solid or inter-
mediate consistency obtained from animal or vegetable
material. The component used to prepare extracts may
undergo pretreatment, such as inactivation of enzymes,
milling or degreasing. The extract can be prepared by
percolation, steeping, or other suitable and validated
methods, using ethanol, water or another solvent, which
varies according to the needs of each material used. After
this process, undesirable materials can be eliminated.
Basile et al. [34] demonstrated in vitro that the acetone
extract of the fruits of Feijoa sellowiana (Berg.) Burret.
(Myrtaceae) has significant anti-H. pylori activity. This
activity can be explained by the presence of the flavone
compound, which when measured alone had higher ac-
tivity against this bacterium compared to the metronida-
zole (0.5 μg/mL) control.
Bonamin et al. [35] evaluated the healing process and
anti-H. pylori activity mediated by a methanol extract
(ME) and an alkaloid-enriched fraction (EAE) of Strychnos
pseudoquina A. St. Hil. (Loganiaceae). Administrationd Material Type of
Analysis
Ref.
Acetone Extract In vitro [34]
Methanol extract/
alkaloid enriched fraction
In vitro and in vivo [35]
Ethanol Extract In vitro [4]
Ethanol Extract In vitro [4]
Ethanol Extract In vitro [4]
Ethanol Extract In vitro [4]
nd leaves Ethanol Extract In vitro [4]
parts Ethanol Extract In vitro [4]
Ethanol Extract In vitro [4]
Methanol extract In vitro [36]
Methanol extract In vitro [36]
Methanol extract In vitro [37]
Methanol extract In vitro [37]
Methanol extract In vitro [38]
Methanol extract In vitro and in vivo [39]
Hydroalcoholic extract In vitro and in vivo [40]
Methanol extract In vitro and in vivo [41]
der branches Aqueous extract In vitro [42]
Ethanol Extract In vitro [43]
Aqueous extract In vitro [44]
Extract/acid and
neutral fractions
In vitro and in vivo [51]
Bonifácio et al. Annals of Clinical Microbiology and Antimicrobials 2014, 13:54 Page 6 of 10
http://www.ann-clinmicrob.com/content/13/1/54over 14 days in rats with chronic gastric ulcers induced by
5% acetic acid (an experimental model that accurately
reflects human gastrointestinal disease) showed that EAE
significantly reduced the edge of the internal (42%) and
external (38%) injury areas using microscopic analysis.
Animals treated with EAE exhibited stimulation of a few
proliferation factors through increase of the height of the
epithelial regeneration area and expression of PCNA in
the nucleus. The number of vessels in the gastric mucosa
of rats treated with EAE was significant increased (four
times more than the treatment vehicle) over vessels that
stimulate cell proliferation in the scarred region. These re-
sults suggest that the vascularization coating in the ulcera-
tive region is involved with the healing action of the
alkaloid fraction of S. pseudoquina. The minimum inhibi-
tory concentration (MIC) of 75 mg/mL from EAE showed
effective in vitro anti-H. pylori activity. EAE was also very
effective in the superoxide dismutase release process,
which is an important protective factor against bacterial
agents.
Cogo et al. [4] determined whether the use of traditional
medicinal plants used in the treatment of gastrointestinal
diseases actually presented pharmacological effects or if
they are simply based on popular use. Within this con-
text, extracts obtained from Bixa orellana L. (Bixaceae),
Chamomilla recutita L. (Asteraceae), Ilex paraguariensis
A. St.-Hil. (Aquifoliaceae), Malva sylvestris L. (Malvaceae),
Plantago major L. (Plantaginaceae) and Rheum rhaponti-
cum L. (Polygonaceae), all commonly used in the treat-
ment of gastrointestinal diseases, were evaluated for their
anti-H. pylori activity against standard (ATCC) and clin-
ical strains. The results showed that the extracts obtained
from B. orellana L., C. recutita L. I. paraguariensis A.
St.-Hil and M. sylvestris L. inhibited the in vitro growth
of H. pylori.
Hajimahmoodi et al. [36] evaluated the in vitro anti-H.
pylori activity of methanol extracts from 23 medicinal
plants used in the treatment of gastrointestinal disor-
ders. Plants were selected on the basis of traditional me-
dicinal practices by the Iranian community. Among these,
only the extracts of Punica granatum L. (Punicaceae) and
Juglans regia L. (Juglandaceae) exhibited high activity
against H. pylori strains, with inhibition zones of 39
and 16 mm, respectively, according to the agar diffu-
sion technique.
Kushima et al. [37] studied methanol extracts (ME)
from the leaves of Davilla elliptica St. Hil. (Dilleniaceae)
and Davilla nitida (Vahl.) Kubitzki. (Dilleniaceae) to
examine their anti-ulcerogenic, immunological and anti-
H. pylori activities. Both extracts protected the gastric
mucosa, although D. nitida (MIC 125 μg/mL) showed bet-
ter activity compared to D. elliptica (MIC 250 μg/mL).
The activity demonstrated is probably explained by
the greater quantities of components such as terpenes,flavonoids, tannins, and other compounds present in
D. nitida.
Lima et al. [38] observed that in addition to healing
and antidiarrheal properties, a methanol extract of leaves
of Byrsonima fagifolia Niedenzu (IK.) (Malpighiaceae)
presented antibacterial activity against standard strains
of Escherichia coli, Staphylococcus aureus and Helicobac-
ter pylori, with an MIC for the last two microorganisms
of 250 μg/mL.
Mazzolin et al. [39] assessed the gastro-protective,
anti-diarrheal, anti-hemorrhagic and mutagenic potential
of a methanol extract from the bark of Qualea parviflora
Mart., a plant belonging to the Vochysiaceae family
native to the Brazilian savannah region. This plant is eth-
nopharmacologically reputed for its important properties
in gastro-pathogenic cases and showed remarkable anti-
microbial activity when tested against H. pylori. Thus,
with an MIC of 75 μg/mL, the extract was classified as
promising for the inhibition of microorganism. Based on
the relevance of the results, methods were developed to
assess its gastro-protective potential, with innovative
results that expanded the therapeutic and prophylactic
possibilities of the herbal compound.
Other studies have also focused on the gastro-protective
action of plant products based on ethnopharmacological
beliefs of anti-hypertensive properties, treatment of gastric
ulcers, inflammatory diseases and stomach disorders. For
example, Moraes et al. [40] demonstrated the anti-H.
pylori potential of the hydroalcoholic extract originating
from the bark of Hancornia speciosa Gomez (Apocynaceae),
a medium-sized tree popularly known as “mangabeira”
found in the Brazilian savannah region, using in vivo
and in vitro approaches. The authors observed that the
extract was able to inhibit bacterial growth at an MIC
of 125 μg/mL using an in vitro approach. In the experi-
mental in vivo model, the extract was shown to be
effective in gastroprotective and antiulcer performance.
The same inhibition values were obtained by Santos
et al. [41] when investigating the antimicrobial profile
of the methanol extract of leaves from Byrsonima inter-
media A. Juss. (Malpighiaceae) against the same strain.
The analysis was performed by means of in vitro screening
and in vivo models from rodent carriers of duodenal
ulcer caused by various agents, such as non-steroidal anti-
inflammatory drugs and chemical solvents; moreover, a
significant antidiarrheal potential was shown when the
extract was assessed against intestinal motility.
Stege et al. [42] showed the anti-H. pylori action of the
aqueous extracts from Larrea divaricata Cav. (Zygophyl-
laceae) against strains highly resistant to conventional
drugs. A standard strain (ATCC) and six strains of clin-
ical origin were used, all resistant to clarithromycin and
four resistant to metronidazole. The plant extract exhib-
ited activity against all strains.
Table 2 Anti-Helicobacter pylori activity of essential oils
Scientific name Family Type of
Analysis
Ref.
Allium sativum L. Liliaceae In vitro [56]
Nepeta camphorata L. Lamiaceae In vitro [57]
Nepeta argolica ssp. dirphya Lamiaceae In vitro [57]
Cymbopogon citratus (DC) Stapf. Poaceae In vitro
and in vivo
[58]
Cupressus sempervirens L. Cupressaceae In vitro [58]
Juniperus communis L. Cupressaceae In vitro [58]
Melaleuca alternifólia, Cheel Myrtaceae In vitro [58]
Aloysia citrodora Palàu Verbenaceae In vitro [58]
Ocimum basilicum L. Lamiaceae In vitro [58]
Mentha piperita L. Lamiaceae In vitro [58]
Origanum marjorana L. Lamiaceae In vitro [58]
Eucalyptus globulus Labill Myrtaceae In vitro [58]
Ravensara aromatica Sonnerat Lauraceae In vitro [58]
Citrus limonum Risso Rutaceae In vitro [58]
Rosmarinus officinalis L. Lamiaceae In vitro [58]
Lavandula latifolia Medik. Lamiaceae In vitro [58]
Myrtus communis L. Myrtaceae In vitro [59]
Citrus lemon Rutaceae In vitro [61]
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tion of mushrooms by the general population in recent
years. Mushrooms have been gaining ground in the cu-
linary world because they have an exotic taste, are highly
nutritious and are a source of protein and minerals. The
scientific community has been searching for the applic-
ability of these products given their use against patho-
genic microorganisms. Shang et al. [43] determined the
activity of 14 ethanol extracts of Chinese mushrooms
used for food and prophylactic purposes against strains
of Helicobacter pylori from standard (ATCC) and clinical
sources obtained from gastric biopsies of patients with
gastric ulcers. All of the extracts were effective against
all strains used in the study. Furthermore, the presence
of antibodies against H. pylori was observed from spe-
cific tests for this purpose.
Cellini et al. [44], Sivam et al. [45], and Canizares et al.
[46] highlighted the activity of the aqueous extract of
garlic against H. pylori. A significant synergistic effect
was observed by Jonkers et al. [47] with the aqueous
extract of garlic and the drug omeprazole, which showed
a significant increase in activity compared to results ob-
tained by each component separately. Pharmacokinetic
interactions between the extract and the drug may occur
during the processes of absorption, distribution, metab-
olism and excretion. In the case of interactions involved
in the absorption process, there may be a decrease or
increase in the amount of drug absorbed or in the rate
of absorption, resulting in a decrease or increase in the
intensity of the pharmacological effect obtained. Phyto-
chemicals present in the extract may also interact with
ATP-dependent protein transporters, such as intestinal
P-glycoprotein or other proteins that facilitate drug ef-
flux, thereby changing its bioavailability. However, inter-
actions between drugs and plant extracts reported in the
literature include alterations in the metabolism of the
drug. These effects are mostly due to compounds that
cause induction or inhibition of the enzymes responsible
for oxidative metabolism belonging to the cytochrome
P450 (CYP) family, the main system used to eliminate
drugs from the body [48-50].
The resin of Pistacia lentiscus (L.) var. chia (Duham),
an evergreen shrub belonging to the family Anacardia-
ceae uniquely cultivated in southern Chios, is known as
mastic. Mastic gum has exhibited anti-H. pylori activity
against several gastrointestinal diseases. Paraschos and
co-workers [51] studied the in vitro and in vivo activities
of Chios mastic gum extracts and its constituents against
H. pylori. The active mastic constituents were obtained
by separation of total mastic extract without polymer
into an acidic and a neutral fraction. Both fractions were
characterized by nuclear magnetic resonance and mass
spectroscopy to elucidate the structure of the compo-
nents. The major triterpenic acids were found in the acidfraction, and triterpenic alcohols and aldehydes com-
posed the neutral fraction. The in vitro results using
the mastic total extract, fractions and pure compounds
showed that the most active extract was the acid frac-
tion, presenting a minimum bactericidal concentration
of 0.139 mg/ml, while isomasticadienolic acid was con-
sidered the most active pure compound (minimum bac-
tericidal concentration of 0.202 mg/ml). Approximately
1 month after being infected with H. pylori, mice were
treated over a 3-month period with extract diluted in
ethanol and then dissolved in water. These in vivo re-
sults showed a statistically significant reduction in H.
pylori viable counts in the group treated with total mas-
tic extract without polymer. PCR, serology, H. pylori cul-
ture and histopathologic evaluation of the gastric mucosa
confirmed these results, indicating that mastic gum may
be effective in reducing H. pylori colonization.
Other studies of great importance are directed towards
the use of essential oils (Table 2) for the treatment of
diseases caused by pathogenic and opportunistic micro-
organisms, such as the use of essential oils in the search
for new compounds endowed with therapeutic potential.
Essential oils or scents are aromatic compounds found
in different plant organs. They are also called volatile oils
or ethereal oils, as they have a high degree of evapor-
ation when exposed to air at room temperature; it is this
feature that confers the significant odor to plants, both
for attraction of pollinators and as insect and herbivore
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the medical field by presenting antimicrobial activities of
extreme value with regards to drug action against patho-
genic or opportunistic microorganisms, including anti-
fungal and antibacterial action. Because the compounds
have a complex constitution, the profile exerted against
microorganisms is directly related to this feature; for ex-
ample, the presence of terpenes, which are secondary me-
tabolites of plants with interesting therapeutic properties,
have been studied by the scientific community in recent
years. The antimicrobial activity demonstrated by terpenes
is attributed to their interference with the integrity and
functioning of the cell membrane through induction of
changes in membrane potential, loss of cytoplasmic ma-
terial and inhibition of the respiratory chain [54,55].
Studies with the aim to elucidate the anti-Helicobacter
pylori profile presented by essential oils have been devel-
oped in recent years because of the need for further drug
options in the treatment of disorders arising from this
type of infection. This fact is justified by the increased
number of strains resistant to the standard drug therapy
used in clinical practice, such as clarithromycin, the drug
most frequently used as a therapeutic agent, and the lack
of an ideal drug regimen with 100% safe applicability [8].
To broaden the knowledge of the anti-H. pylori potential
of essential garlic oil, Otha et al. [56] tested compounds
isolated from crude oil and obtained MIC values ranging
from 10 to 25 μg/mL.
Other antimicrobial profiles of essential oils are repor-
ted in the literature. For example, Kalputzakis et al. [57]
observed antibacterial action against clinical H. pylori
strains extracted from biopsies performed on adults and
children from two species of plants from the Nepeta
genus, Nepeta camphorata L. and Nepeta argolica ssp.
dirphya, belonging to the Lamiaceae family. The profile
established by the essential oils of the two species was
shown to be relevant, with minimum inhibitory concen-
trations (MIC) of 128 and 64 μg/mL for N. camphorata
and N. argolica ssp. dirphya, respectively. Four com-
pounds of the two species were also isolated and tested,
presenting MICs ranging from 16 to 64 μg/mL for the
same strains. The results obtained from the isolated
substances confirm that flavonoids are mainly respon-
sible for the antimicrobial activity for products derived
from plant sources, as these substances were character-
ized as flavonoid derivatives.
Ohno et al. [58] reported the action of 13 essential
oils against strains of H. pylori from clinical and stand-
ard origin (ATCC). The study found activity against all
strains tested with oils extracted from Cupressus sem-
pervirens, Juniperus communis Melaleuca alternifolia,
Lippia citriodora, Ocimum basilicum, Mentha piperita,
Origanum majorana, Eucalyptus globulus., Ravensara aro-
matica, Citrus limonum, Cymbopogon citratus, Rosmarinusofficinalis and Lavandula latifolia. The same sensitivity
profile was observed by Deriu et al. [59] in 2007, who
investigated the activity of the essential oil of Myrtus
communis L. against ten clinical isolates of Helicobacter
pylori with a resistant profile for triple therapy with
metronidazole, clarithromycin and levofloxacin.
The essential oil of Sicilian lemon (Citrus lemon Burm.
Rutaceae) is classified as a potentially promising product
against gastrointestinal diseases [60]. A study regarding
its antimicrobial potential against Helicobacter pylori by
Rozza et al. [61] revealed a minimum inhibitory concen-
tration of 125 μg/mL. Furthermore, the authors performed
a phytochemical analysis to identify the compounds pre-
sent in the oil. Approximately 17 compounds were identi-
fied, of which 13 were identified by gas chromatography.
The authors characterized monoterpene limonene as the
major constituent of the essential oil, equivalent to ap-
proximately 70.75% of the total product. Moreover, the
presence of β -pinene was also detected at a concentration
of 13.19%. The antimicrobial profile of the two major iso-
lated compounds resulted in MICs of 75 μg/mL and
500 μg/mL for limonene and β-pinene, respectively.
Thus, the results were able to attribute limonene as the
main compound responsible for the anti-Helicobacter
pylori activity.
Conclusion
This review demonstrates the grandiosity of the use
of compounds derived from natural products against
Helicobacter pylori and denotes the need for scientific
and technological expansion regarding these agents.
Future work focused on promoting a therapeutic arsenal
endowed with significant pharmacological actions and low
toxicity and cumulative effects is required.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
BVB: Participated in the literature review and in the writing of this review.
MAdSR: Participated in the literature review and in the writing of this review.
PBdS: Participated in the literature review and in the writing of this review.
TMB: Supervised the literature search and reviewed the review. All authors
read and approved the final manuscript.
Authors’ information
Bruna Vidal Bonifácio has a Pharmacist degree (2010) and received an M.Sc.
(2014) degree in Pharmaceutical Sciences at the School of Pharmaceutical
Sciences of São Paulo State University. She is currently working on her Ph.D.
at the same university, and her primary area of research is the discovery of
medicinal plants with antimicrobial activity, including anti-Helicobacter pylori
properties and the use of nanotechnology techniques to improve their
potential applications.
Matheus Aparecido dos Santos Ramos has a Biochemical Pharmacist degree
(2012) and is a student in the Master’s degree program in Pharmaceutical
Sciences of the School of Pharmaceutical Sciences of Sao Paulo State
University UNESP/FCFAR. His work in the area of nanotechnology involves its
application to vulvovaginal candidiasis therapy and gastrointestinal diseases,
along with the use of herbal medicines. He has experience in microbiology
Bonifácio et al. Annals of Clinical Microbiology and Antimicrobials 2014, 13:54 Page 9 of 10
http://www.ann-clinmicrob.com/content/13/1/54with emphasis on clinical mycology and in environmental and cosmetic
microbiology.
Patricia Bento da Silva received Chemistry (2005), M.Sc. (2008) and Ph.D.
(2012) degrees in inorganic chemistry involving “inorganic compounds
applied to tuberculosis and gastrointestinal diseases treatment” from the
Chemistry Program of IQAR/UNESP. Currently, she is a postdoctoral
researcher at the School of Pharmaceutical Sciences of Sao Paulo State
University and works with nanotechnology applied to tuberculosis therapy.
Tais Maria Bauab is a Pharmacist (1979), M.Sc. (1989) in Microbiology and
Immunology from Federal University of Sao Paulo and Ph.D. (2000) in
Biological Sciences from Sao Paulo State University. Presently, she is an
Assistant Professor at the School of Pharmaceutical Sciences of Araraquara-
Sao Paulo State University. Her primary line of research is the discovery of
antimicrobial activity of medicinal plants against several microorganisms,
especially Helicobacter pylori.
Author details
1Department of Biological Sciences, School of Pharmaceutical Sciences, São
Paulo State University, Rodovia Araraquara-Jaú, km 01, Araraquara, SP CEP
14801-902, Brazil. 2Department of Drugs and Medicine, School of
Pharmaceutical Sciences, São Paulo State University, Rodovia Araraquara-Jaú,
km 01, Araraquara, SP CEP 14801-902, Brazil.
Received: 20 August 2014 Accepted: 24 October 2014References
1. Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon ATR, Bazzoli F,
Gensini GF, Gisbert JP, Graham DY, Rokka T, El-Omar EM, Kuipers EJ:
Management of Helicobacter pylori infection-the maastricht IV/ florence
consensus report. Gut 2012, 61:646–664.
2. Fock KM, Katelaris P, Sugano K, Neg TL, Hunt R, Talley NJ, Lam SK, Xiao S,
Tan HJ, Wu CY, Jung HC, Hoang BH, Kachintorn U, Goh KL, Chiba T, Rani AA:
Second asia-pacific consensus guidelines for Helicobacter pylori infection.
J Gastroen Hepatol 2009, 24:1587–1600.
3. Tim Cushnie TP, Lamb AJ: Recent advances in understanding the
antibacterial properties of flavonoids. Int J Antimicrob Ag 2011, 38:99–107.
4. Cogo LL, Monteiro CLB, Miguel MD, Miguel OG, Cunico MM, Ribeiro ML,
Camargo ER, Kussen GMB, Nogueira KS, Costa LMD: Anti- Helicobacter
pylori activity of plant extracts traditionally used for the treatment of
gastrointestinal disorders. Braz J Microbiol 2010, 41:304–309.
5. Newman DJ, Cragg GM: Natural products as sources of new drugs over
the last 25 years. J Nat Prod 2007, 70:461–477.
6. Amaral MFZ, Bara MTF: Avaliação da atividade antifúngica de extratos de
plantas sobre o crescimento de fitopatógenos. REF 2005, 2:5–8.
7. Das K, Tiwari RKS, Shrivastava DK: Techniques for evaluation of medicinal
plant products as antimicrobial agent: current methods and future
trends. J Med Plants Res 2010, 4:104–111.
8. Siqueira JS, Lima PSS, Barreto AS, Quintans-Júnior LJ: Aspectos gerais nas
infecções por Helicobacter pylori. RBAC 2007, 39:9–13.
9. Mobley HLT, Emdz GL, Hazell ST: Helicobacter pylori: physiology and genetics.
Washington (DC): ASM Press; 2001.
10. Fiorentino M, Ding H, Blanchard TG, Czinn SJ, Sztein MB, Fasano A:
Helicobacter pylori-induced disruption of monolayer permeability and
proinflammatory cytokine secretion in polarized human gastric epithelial
cells. Infect Immun 2013, 81:876–883.
11. Dandlen SA, Lima AS, Mendes MD, Miguel MG, Faleiro ML, Sousa MJ, Pedro
LG, Barroso JG, Figueiredo AG: Antimicrobial activity, cytotoxicity and
intracelular growth of Portuguese Tymus essential oils. Rev Bras Farmacogn
2011, 21:1012–1024.
12. Darini D: Colonização gástrica por Helicobacter pylori associada à citotoxina
do gene A (cagA): relação com proliferação celular e apoptose, PhD thesis.
Universidade de São Paulo; 2004
13. Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, Terao D,
Amagai K, Hayashi S, Asaka M: Effect of eradication of Helicobacter pylori
on incidence of metachronous gastric carcinoma after endoscopic
resection of early gastric cancer: an open-label, randomized controlled
trial. Lancet 2008, 372:392–397.
14. Egan BJ, Katicic M, Connor HJO, Morain CAO: Treatment of Helicobacter
pylori. Helicobacter 2007, 12:31–37.15. Wu W, Yang Y, Sung G: Recent insights into antibiotic resistance in
Helicobacter pylori eradication. Gastroenterol Res Pract 2012, 2012:1–9.
16. Kuol CH, Hsu PI, Kuo FC, Wang SSWW, Hu HM, Liu CJ, Chuah SK, Chen YH,
Wul DC, Tseng HH: Comparison of 10 day bismuth quadruple therapy
with high-dose metronidazole or levofloxacin for second-line
Helicobacter pylori therapy: a randomized controlled trial. J Antimicrob
Chemother 2013, 68:222–228.
17. Silveira JA, Filho JES, Souza LEO, Souza LBS, Santana WJ, Coutinho HDM:
Virulence factors and epidemiologic traits of Helicobacter pylori. Rev Med
Ana Costa 2005, 1:1–10.
18. Gürbüz AK, Küçükkardali Y, Yazgan Y, Ozel M, Polat T: Does eradication of
Helicobacter pylori infection reduce hypergastrinema during long term
therapy with proton pump inhibitors? Turk J Gastroenterol 2002,
13:159–163.
19. Weeks DL, Sachs G: Sites of pH regulation of the urea channel of
Helicobacter pylori. Mol Microbiol 2001, 40:1249–1259.
20. Kim D, Park J, Franchi L, Backert S, Núnez G: The Cag pathogenicity island
and interaction between TLR2/NOD2 and NLRP3 regulate IL-1β
production in Helicobacter pylori infected dendritic cells. Eur J Immunol
2013, 43:2650–2658.
21. Suzuki H, Seto K, Mori M, Suzuki M, Miura S, Ishii H: Monochloramine
induced DNA fragmentation in gastric cell line MKN45. Am J Physiol Renal
Physiol 1998, 275:712–716.
22. Lapenna D, Curccurollo F: Hypochlorous acid and its pharmacological
antagonism: an update picture. Gen Pharmacol 1996, 27:1145–1147.
23. Figueiredo C, Machado JC, Pharoah P, Seruca R, Sousa S, Carvalho R,
Capelinha AF, Quint W, Caldas C, Van Doorn LJ, Carneiro F, Sobrinho-Simões
M: Helicobacter pylori and interleukin 1 genotyping: an opportunity to
identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst 2002,
94:1680–1687.
24. Álvares MM, Marino M, Oliveira CA, Mendes CC, Costa ACF, Guerra J,
Queiroz DMM, Nogueira AMMF: Características da gastrite crônica
associada a Helicobacter pylori: aspectos topográficos, doenças
associadas e correlação com o status cagA. J Bras Patol Med Lab 2006,
42:51–59.
25. Banerjee DB, Maity B, Nag SK, Bandyopadhyay SK, Chattopadhyay S: Healing
potential of Picrorhiza kurroa (Scrofulariaceae) rhizomes against
indomethacin-induced gastric ulceration: a mechanistic exploration.
BMC Complement Altern Med 2008, 8:1–14.
26. Silva FM: Dispepsia: caracterização e abordagem. Rev Med 2008,
87:4213–4223.
27. Matsuda NM, Maia CC, Troncon LEA: Dispepsia funcional: revisão de
diagnóstico e fisiopatologia. Diagn Tratamento 2010, 15:114–116.
28. Tipos de Câncer. http://www2.inca.gov.br/wps/wcm/connect/
tiposdecancer/site/home/estomago.
29. Antunes DC, Silva IML, Cruz WMS: Quimioprevenção do câncer gástrico.
Rev Bras Cancerol 2010, 56:367–374.
30. Júnior ONA, Alexandre N, Barboza DRMM, Meireles MS, Pinheiro MV,
Pinheiro ATM: Perfil epidemiológico e histopatológico do câncer gástrico
em um hospital terciário de Fortaleza-CE. Cadernos ESP 2011, 5:26–33.
31. Argent RH, Kidd M, Owen RJ, Thomas RJ, Limb MC, Atherton JC:
Determinants and consequences of different levels of cagA
phosphorylation for clinical isolates of Helicobacter pylori. Gastroenterol
2004, 127:514–523.
32. Silva MKD, Tereza MLF, Fischer RG: Associação da halitose com a presença
de Helicobacter pylori no biofilme dental supragengival em pacientes
com a doença periodontal - um estudo piloto. Braz J Periodontol 2012,
22:63–68.
33. Farmacopéia Brasileira, Parte I: Generalidades: 5a ed., Fiocruz, Brasília. 2010.
34. Basile A, Conte B, Rigano B, Senatore B, Sorbo S: Antibacterial and
antifungal properties of acetonic extract of Feijoa sellowiana fruits and
its effect on Helicobacter pylori growth. J Med Food 2010, 13:189–195.
35. Bonamin F, Moraes TM, Kushima H, Silva MA, Rozza AL, Pellizzon CH, Bauab
TM, Rocha LRM, Vilegas W, Hiruma-Lima CA: Can a Strychnos species be
used as antiulcer agent? ulcer healing action from alkaloid fraction of
Strychnos pseudoquina St. Hil. (Loganiaceae). J Ethnopharmacol 2011,
138:47–52.
36. Hajimahmoodi M, Shams-Ardakani M, Saniee P, Siavoshi F, Mehrabani M,
Hosseinzadeh H, Foroumadi P, Safavi M, Khanavi M, Akbarzadeh T, Shafiee T,
Foroumadi A: In vitro antibacterial activity of some Iranian medicinal
plant extracts against Helicobacter pylori. Nat Prod Res 2011, 25:1059–1066.
Bonifácio et al. Annals of Clinical Microbiology and Antimicrobials 2014, 13:54 Page 10 of 10
http://www.ann-clinmicrob.com/content/13/1/5437. Kushima H, Nishijima CM, Rodrigues CM, Rinaldo D, Sassá MF, Bauab TM,
Di Stasi LC, Carlos IZ, Brito ARMS, Vilegas W, Hiruma-Lima CA: Davilla
elliptica and Davilla nitida: gastroprotective, anti-inflammatory,
immunomodulatory and anti-Helicobacter pylori action. J Ethnopharmacol
2009, 123:430–438.
38. Lima ZP, Santos RC, Torres TU, Sannomiya M, Rodrigues CM, Santos LC,
Pellizzon CH, Rocha LRM, Vilegas W, Brito ARMS, Cardoso CRP, Varanda EA,
Morales HP, Bauab TM, Carli C, Calos IZ, Hiruma-Lima CA: Byrsonima
fagifolia: an integrative study to validate the gastroprotective, healing,
antidiarrheal, antimicrobial and mutagenic action. J Ethnopharmacol 2008,
120:149–160.
39. Mazzolin LP, Nasser ALM, Moraes TM, Santos RC, Nishijima CM, Santos FV,
Varanda EA, Bauab TM, Rocha LRM, Di Stasi LC, Vilegas W, Hiruma-Lima CA:
Qualea parviflora mart.: an integrative study to validate the
gastroprotective, antidiarrheal, antihemorragic and mutagenic action.
J Ethnopharmacol 2010, 27:508–514.
40. Moraes TM, Rodrigues CM, Kushima H, Bauab TM, Vilegas W, Pellizon CH,
Brito AMS, Hiruma-Lima CA: Hancornia speciosa: indications of
gastroprotective, healing and anti-Helicobacter pylori actions.
J Ethnopharmacol 2008, 120:161–168.
41. Santos RC, Kushima H, Rodrigues CM, Sannomiya M, Rocha LRM, Bauab TM,
Tamashiro J, Vilegas W, Hiruma-Lima CA: Byrsonima intermedia A. Juss.:
gastric and duodenal anti-ulcer, antimicrobial and antidiarrheal effects in
experimental rodent models. J Ethnopharmacol 2012, 140:203–212.
42. Stege PW, Davicino RC, Vega AE, Casali YA, Correa S, Micalizzi B:
Antimicrobial activity of aqueous extracts of Larrea divaricata Cav.
(jarilla) against Helicobacter pylori. Phytomedicine 2006, 13:724–727.
43. Shang X, Tan Q, Liu R, Kangying Y, Li P, Zhao G: In vitro anti–Helicobacter
pylori effects of medicinal mushroom extracts, with special emphasis on
the lion’s mane mushroom Hericium erinaceus, (Higher Basidiomycetes).
Int J Med Mushrooms 2013, 15:165–174.
44. Cellini L, Di Campli E, Masulli M, Di Bartolomeo S, Allocati N: Inhibition of
Helicobacter pylori by garlic extract (Allium sativum). Immunol Med Mic
1996, 13:273–277.
45. Sivam GP: Protection against Helicobacter pylori and other bacterial
infections by garlic. J Nutr 2001, 131:1106–1108.
46. Cañizares P, Gracia I, Gómez LA, García A, De Argila CM, Boixeda D, Rafael L:
Thermal degradation of allicin in garlic extracts and its implication on
the inhibition of the in-vitro growth of Helicobacter pylori. Biotechnol Prog
2004, 20:32–37.
47. Jonkers D, Van den Broek E, Van Dooren I, Thijs C, Dorant E, Hageman G,
Stobberingh E: Antibacterial effect of garlic and omeprazole on
Helicobacter pylori. J Antimicrob Chemother 1999, 43:837–839.
48. Cordeiro CHG, Chung MC, Sacramento LVS: Interações medicamentosas de
fitoterápicos e fármacos: Hypericum perforatum e Piper methysticum.
Rev Bras Farmacogn 2005, 15:272–278.
49. Zago JAA, Ushimaru PI, Barbosa LN, Junior AF: Sinergismo entre óleos
essenciais e drogas antimicrobianas sobre linhagens de Staphylococcus
aureus e Escherichia coli isoladas de casos clínicos humanos. Rev Bras
Farmacogn 2009, 19:828–833.
50. Ma J, Zhang L, Brown LM, Li J, Shen L, Pan K, Liu W, Hu Y, Han Z, Mansour
SC, Pee D, Blot WJ, Fraumeni Junior JF, You W, Gail MH: Fifteen-year effects
of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer
incidence and mortality. J Natl Cancer Inst 2012, 104:488–492.
51. Paraschos S, Magiatis P, Mitakou S, Petraki K, Kalliaropoulos A,
Maragkoudakis P, Mentis A, Sgouras D, Skaltsounis AL: In vitro and in vivo
activities of Chios mastic gum extracts and constituents against
Helicobacter pylori. Antimicrob Agents Chemother 2007, 51:551–559.
52. Craveiro AA, Queiroz DC: Óleos essenciais e química fina. Quím Nova 1993,
16:224–228.
53. Simões CM, Schenkel EP, Gosmann G, Mello JCP, Mentz LA, Petrovick PR:
Farmacognosia: da planta ao medicamento. Porto Alegre: UFSC; 2007.
54. Nascimento PFC, Nascimento ALC, Rodrigues CS, Antoniolli AR, Santos PO,
Junior AMB, Trindade RC: Atividade antimicrobiana dos óleos essenciais:
uma abordagem multifatorial dos métodos. Rev Bras Farmacogn 2007,
17:108–113.
55. Qui J, Zhang X, Luo M, Li H, Dong J, Wang J, Leng B, Wang X, Feng H,
Ren W, Deng X: Subinhibitory concentrations of Perilla oil affect the
expression of secreted virulence factor Genes in Staphylococcus aureus.
PLoS One 2011, 6:1–8.56. Otha R, Yamada N, Kaneko H, Ishikawa K, Fukuda H, Fujino T, Suzuki A:
In vitro inhibition of the growth of Helicobacter pylori by oil-macerated
garlic constituents. Antimicrob Agents Chemother 1999, 43:1811–1812.
57. Kalpoutzakis E, Aligannis N, Mentis A, Mitaku S, Charvala C: Composition of
the essential oil of two Nepeta species and in vitro evaluation of their
activity against Helicobacter pylori. Planta Med 2001, 67:880–883.
58. Ohno T, Kita M, Yamaoka Y, Imamura S, Yamamoto T, Mitsufuji S, Kodoma T,
Kashima K, Imanishi J: Antimicrobial activity of essential oils against
Helicobacter pylori. Helicobacter 2003, 8:207–215.
59. Deriu A, Branca G, Molicotti P, Pintore G, Chessa M, Tirillini B, Peglietti B,
Mura A, Sechi LA, Fadda G, Zanetti S: In vitro activity of essential oil of
Myrtus communis L. against Helicobacter pylori. Int J Antimicrob Ag 2007,
30:562–563.
60. Rozza AL, Pellizzon CL: Essential oils from medicinal and aromatic plants:
a review of the gastroprotective and ulcer-healing activities. Fundam Clin
Pharmacol 2012, 27:51–63.
61. Rozza AL, Moraes TM, Kushima H, Tanomoto A, Marques MOM, Bauab TM,
Hiruma-Lima CA, Pellizzon CH: Gastroprotective mechanisms of Citrus
lemon (Rutaceae) essential oil and its majority compounds limonene and
pinene: involvement of heat-shock protein-70, vasoactive intestinal
peptide, glutathione, sulfhydryl compounds, nitric oxide and prostaglandin
E2. Chem Biol Interact 2011, 189:82–89.
doi:10.1186/s12941-014-0054-0
Cite this article as: Bonifácio et al.: Antimicrobial activity of natural
products against Helicobacter pylori: a review. Annals of Clinical
Microbiology and Antimicrobials 2014 13:54.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
